PRN: Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancer

20/mar/2014 15:52:20 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancer


-- The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions

MOUNTAIN VIEW, California, March 20, 2014 /PRNewswire/ -- Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two low-energy X-ray devices, SRT-100™ and SRT-100 Vision™. Low energy X-rays are often used for medical imaging and for the treatment of certain cancers. The SRT-100™ and SRT-100 Vision™ devices are superior to other available treatments of non-melanoma skin cancer and other skin conditions. They offer unrivaled value to patients and physicians through safe, effective, and virtually pain- and scar-free treatment options.

Competing products use electron beams ranging from 1 to 12 mega electron volts (MeV), or decaying isotope-based emitting sources. They are also bulky, complex and expensive to operate and maintain. Furthermore, the patients are subjected to radiation levels many times the energy required for non-melanoma skin cancer treatment, with only a part of the energy being delivered to the surface of the skin.

In contrast, Sensus Healthcare's SRT-100™ and SRT-100 Vision™ use kilovoltage X-rays in the 50 to 100 kilo volts (KV) energy range. The radiation is delivered completely to the surface of the skin, without affecting the underlying healthy tissue and cells. SRT is ideal for irradiating tumorous growths at depths of between 0.5 mm and 5 mm.

SRT-100™ and SRT-100 Vision™ are small footprint and portable devices, similar in size and design to an ultrasound instrument. Interestingly, Sensus' next-generation SRT device, the SRT-100 Vision™, integrates high-resolution ultrasound imaging and laser positioning capabilities to help with the accurate localization, characterization, and topology of lesions. This, in turn, will ensure optimal energy dosage, treatment fractionation and depth of beam penetration.

"SRT-100™ and SRT-100 Vision™ utilize a non-invasive approach that does not leave scars and therefore, eliminates the need for additional follow-up procedures, such as skin grafting and cosmetic reconstructive surgeries," said Frost & Sullivan Research Analyst Bhargav Rajan. "There is no loss of skin and/or sensation, and since it is a non-contact procedure, it is painless. The entire procedure lasts only seconds for each treatment fraction, compared to surgeries and other procedures, which take hours and additional recovery time."

A retrospective assessment of over 1,700 patients who were treated for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) using SRT-100™ showed a 98 percent cure rate over two years, and over 95 percent cure rate over five years. These remarkable cure rates are comparable with those obtained using current clinical standards.

"SRT-100™ has come to be considered medically necessary and/or an adjunctive procedure for the treatment of non-melanoma skin cancers and non-oncological skin conditions such as keloids," noted Rajan. "Due to its record for safety, efficacy, and low risks, it is covered by most insurance companies and Medicare for oncological and non-oncological procedures."

SRT-100™'s penetration potential got a boost with the United States Food and Drug Administration (FDA) 510(K) recently clearing it to treat keloids, which are collagen-based non-malignant scars. With this regulatory approval, SRT-100™ and SRT-100 Vision™ can now be used to treat non-oncological conditions (keloids) and pre-oncological conditions such as actinic keratosis. For all of these applications, the SRT-100™ and SRT-100 Vision™ have FDA 510(K) clearance, the European Union's CE mark, and the ISO quality certification. The company is actively looking at expanding its geographic presence beyond the US, Europe, Australia, Africa, and Canada into additional regions in Europe, Asia, and Latin America.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Sensus Healthcare LLC

Sensus Healthcare LLC (Boca Raton, FL) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities.

Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. 

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation


Mireya Espinoza           
P: 210.247.3870
F: 210.348.1003

blog comments powered by Disqus è un servizio offerto da Factotum Srl